• Plus Therapeutics signed a national coverage agreement with Elevance Health for the CNSide cerebrospinal fluid tumor cell enumeration assay, effective May 1, 2026.
• Agreement covers about 45.4 million people in the US; total contracted coverage for the assay rises to 126 million.
• CNSide test volumes exceed 11,000 since 2020 across more than 120 US cancer institutions, with 92% sensitivity, 95% specificity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250730PRIMZONEFULLFEED9752367) on June 25, 2026, and is solely responsible for the information contained therein.